pharma · EBV-induced Lymphomas · Coronary Artery Disease
Evidence Based Cataract
Evidence Based Cataract Study Group
Evidence Based Cataract patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- THOUSAND OAKS, CA, CN
- Programs
- 10
- Drugs
- 8
- Patents
- 10
Evidence Based Cataract patents
10 pharmaceutical patents indexed for Evidence Based Cataract. 0 expire within 24 months.
Evidence Based Cataract has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12383572
Administration of an anti-activin-a compound to a subject
granted -
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
granted -
US 11541070
Administration of an anti-activin-A compound to a subject
granted -
US 9968586
Mast cell stabilizers treatment for systemic disorders
granted -
US 9962363
Mast cell stabilizers treatment for systemic disorders
granted -
US 9707206
Mast cell stabilizers treatment for systemic disorders
granted -
US 9265749
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted -
US 8410043
Stabilized activin IIB receptor polypeptides and uses thereof
granted -
US 6146653
Pharmaceutical preparation and a method for the treatment of diabetes
expired
Frequently asked questions
How many patents does Evidence Based Cataract have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Evidence Based Cataract patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.